TABLE 1.
Variable | HIV+/HSV-2−, Excluded n = 53 |
HIV+/HSV-2−, Cohort n = 119 |
HIV+/ HSV-2 Nonseroconveters n = 109 |
HIV+/HSV-2 Seroconverters n = 10 |
|
---|---|---|---|---|---|
Age, median (range), y | 36 (23 to 54) | 35 (21 to 56) | 34 (21 to 56) | 36 (31 to 45) | |
Race, no. (%) subjects | |||||
White | 34 (83)* | 91 (76) | 83 (76) | 8 (80) | |
Native American | 0 (0) | 15 (13) | 14 (13) | 1 (10) | |
Black | 2 (5) | 9 (7) | 9 (8) | 0 (0) | |
Asian | 3 (7) | 3 (3) | 2 (2) | 1 (10) | |
Unknown | 2 (5) | 1 (1) | 1 (1) | 0 (0) | |
Ethnicity, no. (%) subjects | |||||
Not Hispanic | 16 (39) | 44 (37) | 39 (36) | 5 (50) | |
Hispanic | 8 (20) | 24 (20) | 22 (20) | 2 (20) | |
Unknown | 17 (41) | 51 (43) | 48 (44) | 3 (30) | |
HIV stage, no. (%) subjects | |||||
Acute | 14 (34) | 30 (25) | 28 (26) | 2 (20) | |
Early | 27 (66) | 89 (75) | 81 (74) | 8 (80) | |
CD4 T-cell count, median (range), cells/mm3 | 431 (123 to 932)† | 520 (107 to 1380) | 510 (107 to 1380) | 545 (314 to 1193) | |
HIV load, median (range), log10 copies/mL | 5.20 (2.88 to 7.28) | 5.04 (1.70 to 7.19) | 5.04 (1.70 to 7.19) | 4.30 (2.89 to 6.86) |
P ≤ 0.015 in comparison to the HIV-1+/HSV-2− cohort studied using the Fisher exact test.
P ≤ 0.018 in comparison to the HIV-1+/HSV-2− cohort studied using the Wilcoxon 2-sample test.